The facility, plans for which were unveiled in January, will produce radiolabelled compounds, including 14-C, for Quotient’s roster of pharmaceutical, biopharmaceutical and medical device developer clients.
The unit was established to act as a hub for Quotient’s labelling business, which was formed through the acquisition of Amersham Radio-labelling from US giant GE Healthcare in mid 2009.
Quotient, which claims the unit houses the “the largest and most experienced team of radiosynthesis chemists in the world,” expects to provide labelled materials for more than 250 customers worldwide.